Drug profile · INN
atezolizumab
TECENTRIQ
atezolizumab (TECENTRIQ) is a programmed cell death 1 ligand 1 inhibitor. Associated with Hoffmann-La Roche. Route of administration: injection. Current US regulatory status: approved.
Drug details — atezolizumab
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- INJECTION
- Patents
- 20
- Programs
- 105
- Data quality
- 0.84
Quick answer
atezolizumab (TECENTRIQ) is a programmed cell death 1 ligand 1 inhibitor. Associated with Hoffmann-La Roche. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Programmed cell death 1 ligand 1 inhibitor
Primary target: Programmed cell death 1 ligand 1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
| NMPA | clinical trials | — |
Recent coverage
Pharma bets on PD-1/VEGF bispecifics: Is lung cancer the wrong target?
While many drugmakers are focused on lung cancer for PD-1/VEGF bispecifics, emerging evidence shows the liver may offer higher value. This analysis covers the mechanism, key players, and strategic implications for pharma teams.
FDA Approves Atezolizumab for ctDNA MRD-Positive MIBC: A New Era for Adjuvant Therapy
The U.S. Food and Drug Administration (FDA) has approved atezolizumab (Tecentriq) for the adjuvant treatment of adult patients with muscle-invasive bladder cancer (MIBC) who have ctDNA molecular residual disease (MRD) positivity after radical cystectomy. This approval signifies a major step forward in personalized adjuvant therapy for this patient population.
FDA Approves Atezolizumab for Muscle-Invasive Bladder Cancer
The FDA has approved Atezolizumab for muscle-invasive bladder cancer, marking a significant advancement in oncology treatment options. This approval has important implications for investors and pharmaceutical teams.
Roche's ctDNA-Guided Approach in Bladder Cancer: A Strategic Win
Roche's innovative ctDNA-guided approach for Tecentriq in post-surgical bladder cancer has garnered significant attention. This article explores the implications for pharmaceutical teams and investors.
Pipeline programs
Related & competitor drugs
Related patents
-
WO 2026114957
DÉRIVÉS DE THIOPHÈNE 2-AMINO-3-CYANO SPIROCYCLIQUES ANNELÉS EN TANT QUE DÉGRADEURS DE KRAS POUR LE TRAITEMENT DU CANCER
granted -
WO 2026114918
DÉRIVÉS DE 2-AMINO-3-CYANO THIOPHÈNE ANNELÉS SPIROCYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE KRAS POUR LE TRAITEMENT DU CANCER
granted -
US 20260146050
KRAS DEGRADING COMPOUNDS COMPRISING SPIROCYCLIC ANNULATED 2 AMINO-3-CYANO THIOPHENES
granted -
WO 2026109631
UTILISATION DE PROTÉINES ENGAGEANT LES LYMPHOCYTES T DANS LE TRAITEMENT DU CANCER
granted -
WO 2026099754
MÉTHODE DE RÉDUCTION DE L'EXCRÉTION VIRALE, DE COLONISATION DE TISSU ET DE DÉPLÉTION LYMPHOÏDE PROVOQUÉES PAR OU ASSOCIÉES À UNE INFECTION PAR PCV2
granted -
US 20260116870
NOVEL NAV 1.1 POTENTIATORS
granted -
WO 2026082899
ARN POUR LA PREVENTION OU LE TRAITEMENT DE LA TUBERCULOSE
granted -
WO 2026082715
DÉPLÉTION DES MACROPHAGES ET VIRUS DE LA STOMATITE VÉSICULAIRE POUR LE TRAITEMENT DU CANCER
granted -
US 20260096994
SOLID DISPERSIONS HAVING STABILIZED EMULSION PARTICLES
granted -
WO 2026068864
DOMAINES CH1 ET CL MODIFIÉS POUR LA PRÉVENTION DU MÉSAPPARIEMENT DE CHAÎNE
granted -
WO 2026062193
COMPOSITIONS ET PROCÉDÉS
granted -
WO 2026058153
UTILISATIONS DE RÉCEPTEUR DE LYMPHOCYTES T DE VPH-16 ET COMPOSITIONS ASSOCIÉES
granted -
WO 2026057625
PEPTIDOGLYCANE HYDROLASES AYANT UN DOMAINE CHAP AVEC SITE ACTIF MODIFIÉ
granted -
WO 2026057626
PEPTIDOGLYCANE HYDROLASES AYANT DE MULTIPLES DOMAINES ENZYMATIQUEMENT ACTIFS
granted -
WO 2026047601
RÉCEPTEURS DE LYMPHOCYTES T (TCR)
granted -
WO 2026046899
PYRAZOLO[5,1-f][1,2,4]TRIAZIN-4-ONES EN TANT QU'INHIBITEURS DE NOX4
granted -
WO 2026041123
VACCINS À VECTEUR DEV CONTRE LA GRIPPE AVIAIRE
granted -
WO 2026033380
PROCESSUS DE PRÉPARATION DE COMPLEXES OLIGOSACCHARIDIQUES
granted -
WO 2026027695
COMPOSITIONS ET PROCÉDÉS
granted -
WO 2026021698
PARTICULE D'ACIDE NUCLÉIQUE
granted
Frequently asked questions
What is atezolizumab?
atezolizumab (TECENTRIQ) is a programmed cell death 1 ligand 1 inhibitor. Associated with Hoffmann-La Roche. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for atezolizumab?
TECENTRIQ is a marketed brand name for atezolizumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of atezolizumab?
atezolizumab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.